Cargando…
ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report
Herein, we describe an extremely rare experience of a patient with liver cirrhosis from hepatitis C virus (LC-HCV) who underwent an ABO-incompatible living donor liver transplantation (ABO-I-LDLT) using a hepatitis B core antibody (HBc-Ab) positive donor's liver graft. A 47-year-old Japanese wo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090435/ https://www.ncbi.nlm.nih.gov/pubmed/25045572 http://dx.doi.org/10.1155/2014/507621 |
_version_ | 1782480628040597504 |
---|---|
author | Umemura, Akira Nitta, Hiroyuki Sasaki, Akira Takahara, Takeshi Hasegawa, Yasushi Wakabayashi, Go |
author_facet | Umemura, Akira Nitta, Hiroyuki Sasaki, Akira Takahara, Takeshi Hasegawa, Yasushi Wakabayashi, Go |
author_sort | Umemura, Akira |
collection | PubMed |
description | Herein, we describe an extremely rare experience of a patient with liver cirrhosis from hepatitis C virus (LC-HCV) who underwent an ABO-incompatible living donor liver transplantation (ABO-I-LDLT) using a hepatitis B core antibody (HBc-Ab) positive donor's liver graft. A 47-year-old Japanese woman with end stage LC-HCV, as a recipient, was preoperatively administered rituximab, mycophenolate mofetil, and steroids without plasma exchange. A routine ABO-I-LDLT procedure was applied using her daughter's HBc-Ab positive liver graft. Prophylaxis of the hepatitis B virus (HBV) infection using hepatitis B immunoglobulin (HBIG) and entecavir had been properly administered. Three months after the ABO-I-LDLT, HCV hepatitis relapsed. To date, this patient has been under antiviral therapy and prophylaxis of HBV infection using HBIG, while entecavir has been continued. The cognitions and techniques with regard to ABO-I-LDLT, prophylaxis of HBV cross infection, various patterns of immunosuppression, and antiviral therapy for HCV relapse are indispensable in managing a transplant recipient. According to the prophylaxis of HBV cross infection under ABO-I-LDLT, it may be very important to keep the HBs-Ab titer higher than usual for HBV naïve recipients, because severe systemic immunosuppression can cause de novo hepatitis. |
format | Online Article Text |
id | pubmed-4090435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40904352014-07-20 ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report Umemura, Akira Nitta, Hiroyuki Sasaki, Akira Takahara, Takeshi Hasegawa, Yasushi Wakabayashi, Go Case Rep Transplant Case Report Herein, we describe an extremely rare experience of a patient with liver cirrhosis from hepatitis C virus (LC-HCV) who underwent an ABO-incompatible living donor liver transplantation (ABO-I-LDLT) using a hepatitis B core antibody (HBc-Ab) positive donor's liver graft. A 47-year-old Japanese woman with end stage LC-HCV, as a recipient, was preoperatively administered rituximab, mycophenolate mofetil, and steroids without plasma exchange. A routine ABO-I-LDLT procedure was applied using her daughter's HBc-Ab positive liver graft. Prophylaxis of the hepatitis B virus (HBV) infection using hepatitis B immunoglobulin (HBIG) and entecavir had been properly administered. Three months after the ABO-I-LDLT, HCV hepatitis relapsed. To date, this patient has been under antiviral therapy and prophylaxis of HBV infection using HBIG, while entecavir has been continued. The cognitions and techniques with regard to ABO-I-LDLT, prophylaxis of HBV cross infection, various patterns of immunosuppression, and antiviral therapy for HCV relapse are indispensable in managing a transplant recipient. According to the prophylaxis of HBV cross infection under ABO-I-LDLT, it may be very important to keep the HBs-Ab titer higher than usual for HBV naïve recipients, because severe systemic immunosuppression can cause de novo hepatitis. Hindawi Publishing Corporation 2014 2014-06-22 /pmc/articles/PMC4090435/ /pubmed/25045572 http://dx.doi.org/10.1155/2014/507621 Text en Copyright © 2014 Akira Umemura et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Umemura, Akira Nitta, Hiroyuki Sasaki, Akira Takahara, Takeshi Hasegawa, Yasushi Wakabayashi, Go ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report |
title | ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report |
title_full | ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report |
title_fullStr | ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report |
title_full_unstemmed | ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report |
title_short | ABO-Incompatible Living Donor Liver Transplantation from Hepatitis B Core Antibody Positive Donor to Hepatitis C Liver Cirrhosis Recipient: A Case Report |
title_sort | abo-incompatible living donor liver transplantation from hepatitis b core antibody positive donor to hepatitis c liver cirrhosis recipient: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090435/ https://www.ncbi.nlm.nih.gov/pubmed/25045572 http://dx.doi.org/10.1155/2014/507621 |
work_keys_str_mv | AT umemuraakira aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport AT nittahiroyuki aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport AT sasakiakira aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport AT takaharatakeshi aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport AT hasegawayasushi aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport AT wakabayashigo aboincompatiblelivingdonorlivertransplantationfromhepatitisbcoreantibodypositivedonortohepatitisclivercirrhosisrecipientacasereport |